The Proteomics Research Platform develops and applies advanced mass spectrometry-based technologies to define the molecular organisation, signalling and remodelling of biological systems in health and disease. The platform supports projects from experimental design and sample preparation through quantitative analysis, computational interpretation and biological validation, enabling discovery of disease mechanisms, biomarkers, therapeutic targets and drug responses.
Our capabilities span deep proteome profiling, post-translational modification analysis, subcellular and spatial proteomics, protein interaction studies, biofluid proteomics, extracellular vesicle analysis and integrated multi-omics. We combine selective enrichment and fractionation strategies with high-resolution Orbitrap mass spectrometry, data-independent and multiplexed acquisition, advanced bioinformatics, machine learning and systems biology.
Recent platform-led research has established region-specific nuclear enrichment and chamber-resolved cardiac proteome maps, subcellular proteomic frameworks for defining heart organisation, multi-omic analysis of circulating extracellular vesicles, translational proteomics of myocardial injury and inflammation, and proteome-wide evaluation of engineered nanovesicle and biomaterial-based therapeutic strategies. These approaches connect molecular discovery to functional and translational outcomes.
What we provide
- Experimental design, feasibility assessment, power and replication guidance, sample randomisation and quality-control planning.
- Protein extraction and low-input preparation from cells, fresh or frozen tissue, fixed tissue, clinical biopsies, plasma, serum and other biofluids.
- Subcellular, organelle and spatial fractionation, including nuclear enrichment, membrane/surfaceome analysis, secretome profiling and extracellular vesicle enrichment.
- Whole-proteome, affinity-purification and immunoprecipitation workflows for protein abundance, interaction and complex analysis.
- Label-free, data-independent acquisition, TMT and SILAC quantitative proteomics.
- Post-translational modification analysis, including phosphoproteomics, site localisation and kinase/pathway inference.
- Plasma and blood proteomics, including deep profiling, targeted depletion or enrichment, and integration with extracellular vesicle and lipidomic measurements.
- Sequential and integrated proteomic–lipidomic workflows that maximise information from limited biological material.
- High-resolution LC–MS/MS using Orbitrap instrumentation, supported by robust chromatography, fractionation and peptide-clean-up strategies.
- Bioinformatics, statistical modelling, pathway and network analysis, machine learning, multi-omic integration, data visualisation and biological interpretation.
- Targeted verification and support for orthogonal validation using molecular, imaging and functional assays.
Advanced analytical approaches
Spatial and subcellular proteomics
Fractionation and enrichment workflows resolve where proteins are organised within cells and tissues, rather than measuring abundance alone. Applications include organelle mapping, nuclear proteomics, chamber- and region-resolved cardiac analysis, membrane and coronary-accessible surfaceome profiling, and analysis of disease-associated protein redistribution.
Multi-omic integration
Proteomic data can be integrated with lipidomics, metabolomics, transcriptomics, imaging and functional phenotyping. Sequential lipid–protein analytical workflows and extracellular-vesicle multi-omics improve molecular coverage from limited samples and reveal coordinated protein–lipid signatures.
Biofluid and extracellular-vesicle proteomics
The platform supports plasma, serum and extracellular-vesicle studies using enrichment, fractionation and sensitive acquisition strategies. Applications include biomarker discovery, molecular classification, EV heterogeneity, surface-protein analysis and translation to diagnostic or therapeutic development.
Post-translational and signalling analysis
Phosphoproteomics and related enrichment strategies define dynamic signalling responses, regulatory sites, kinase networks and early molecular mechanisms following injury, treatment or therapeutic intervention.
Translational and therapeutic proteomics
Proteomics is applied to preclinical and clinically relevant models to determine mechanism of action, drug response, inflammatory and fibrotic remodelling, nanoparticle cargo, biodistribution-associated tissue responses and molecular restoration following therapy.
Computational and systems analysis
Quantitative proteomic datasets are analysed using rigorous statistical workflows, pathway and network modelling, machine learning and integration with public or project-specific datasets. The aim is to move from protein lists to interpretable mechanisms, candidate targets and testable biological models.
Applications
- Cardiovascular remodelling, myocardial infarction, ischaemia–reperfusion injury and heart failure.
- Metabolic, vascular, inflammatory and fibrotic disease.
- Biomarker and diagnostic development.
- Drug-response and mechanism-of-action studies.
- Extracellular vesicle biology and circulating vesicle profiling.
- Nanoparticle, lipid nanoparticle and nanovesicle therapeutics.
- Regenerative medicine, biomaterials and tissue engineering.
- Cancer, infectious disease and other complex biological systems.
- Model and non-model organism proteomics.
